- Home
- UBFO vs CRVS Comparison
UBFO vs CRVS Comparison
Compare UBFO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBFO
- CRVS
- Stock Information
- Founded
- UBFO 1987
- CRVS 2014
- Country
- UBFO United States
- CRVS United States
- Employees
- UBFO N/A
- CRVS N/A
- Industry
- UBFO Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- UBFO Finance
- CRVS Health Care
- Exchange
- UBFO Nasdaq
- CRVS Nasdaq
- Market Cap
- UBFO 175.9M
- CRVS 206.5M
- IPO Year
- UBFO N/A
- CRVS 2016
- Fundamental
- Price
- UBFO $9.06
- CRVS $4.43
- Analyst Decision
- UBFO
- CRVS Strong Buy
- Analyst Count
- UBFO 0
- CRVS 3
- Target Price
- UBFO N/A
- CRVS $16.33
- AVG Volume (30 Days)
- UBFO 28.2K
- CRVS 1.4M
- Earning Date
- UBFO 04-17-2025
- CRVS 05-08-2025
- Dividend Yield
- UBFO 5.25%
- CRVS N/A
- EPS Growth
- UBFO N/A
- CRVS N/A
- EPS
- UBFO 0.77
- CRVS N/A
- Revenue
- UBFO $47,362,000.00
- CRVS N/A
- Revenue This Year
- UBFO N/A
- CRVS N/A
- Revenue Next Year
- UBFO N/A
- CRVS N/A
- P/E Ratio
- UBFO $11.83
- CRVS N/A
- Revenue Growth
- UBFO N/A
- CRVS N/A
- 52 Week Low
- UBFO $7.07
- CRVS $1.75
- 52 Week High
- UBFO $10.49
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- UBFO 56.86
- CRVS 68.59
- Support Level
- UBFO $8.95
- CRVS $3.17
- Resistance Level
- UBFO $9.25
- CRVS $3.71
- Average True Range (ATR)
- UBFO 0.26
- CRVS 0.23
- MACD
- UBFO 0.08
- CRVS 0.08
- Stochastic Oscillator
- UBFO 64.54
- CRVS 95.47
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).